Please assess the completion status of the following clinical trial:

Trial Title: Glucose Optimisation With Angiotensin II Antagonist Losartan (GOAAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension with diastolic blood pressure 95-110 mmHg and systolic blood pressure \< 180 mmHg~* Previously untreated hypertension or treated with monotherapy (but not with ACE-inhibitors or Angiotensin II-receptor blockers)~* Impaired glucose tolerance or impaired fasting glucose (fasting plasma glucose; 6.1-7.0 mmol/l (110-126 mg/dl)~* Age over 18~* Informed consent~* Any one of these: Microalbuminuria (urin excretion \>20 microg/min), dyslipidemia (HDL-cholesterol \<0.9 mmol/l(35 mg/dl), Triglycerides \> 1.7 mmol/l (150 mg/dl), waist to hip-ratio \>0.9 in men and \>0.85 in women, BMI \>28 kg/m2.~Exclusion Criteria:~* Previous or current use of ACE-inhibitors or Angiotensin II-receptor blockers~* Previous or current antidiabetic medications~* Brittle pre-diabetes where the investigator anticipates pharmacological treatment within next 6 months~* Hypertensive patients where the investigator anticipates polytherapy within next 6 months~* Female patient who is pregnant or nursing or planning pregnancy within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).